S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get 12 Months of Stock Picks for $9.00 (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
MarketBeat All Access New Year's Sale - Just $1.00 (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get 12 Months of Stock Picks for $9.00 (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
MarketBeat All Access New Year's Sale - Just $1.00 (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get 12 Months of Stock Picks for $9.00 (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
MarketBeat All Access New Year's Sale - Just $1.00 (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get 12 Months of Stock Picks for $9.00 (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
MarketBeat All Access New Year's Sale - Just $1.00 (Ad)
NASDAQ:TENX

Tenax Therapeutics (TENX) Stock Price, News & Analysis

$0.27
-0.06 (-17.93%)
(As of 12/29/2023 ET)
Today's Range
$0.26
$0.33
50-Day Range
$0.16
$0.62
52-Week Range
$0.15
$4.30
Volume
3.73 million shs
Average Volume
557,417 shs
Market Capitalization
$6.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Tenax Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,085.0% Upside
$6.00 Price Target
Short Interest
Healthy
0.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Tenax Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.35) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars


TENX stock logo

About Tenax Therapeutics Stock (NASDAQ:TENX)

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

TENX Stock Price History

TENX Stock News Headlines

MarketBeat All Access New Year's Sale - Just $1.00
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.
TENX: IND Clears Way for Phase III
Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?
MarketBeat All Access New Year's Sale - Just $1.00
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.
Why Tenax Therapeutics (TENX) Stock Is Up 100%
TENX - Tenax Therapeutics, Inc.
TENX: Prioritizing Levosimendan
Tenax Therapeutics Provides 2023 Business Update
TENX: Patents Guide the Way
TENX Tenax Therapeutics, Inc.
TENX: New Funding Puts Wind in the Sails
Triangle pharma raising millions amid uncertain future
Tenax Therapeutics Down 20% After Offering Gets Priced
See More Headlines
Receive TENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/31/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/12/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TENX
Employees
7
Year Founded
1967

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+2,085.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-11,050,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.65 per share

Miscellaneous

Free Float
23,421,000
Market Cap
$6.55 million
Optionable
Not Optionable
Beta
2.55

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Christopher T. Giordano (Age 48)
    CEO, President & Director
    Comp: $563.04k
  • Mr. Eliot M. Lurier CPA (Age 65)
    Interim Chief Financial Officer
    Comp: $221.7k
  • Dr. Stuart Rich M.D. (Age 73)
    Chairman of Scientific Advisory Board, Chief Medical Officer & Director
    Comp: $416k
  • Ms. Nancy J. M. Hecox
    Executive VP of Legal Affairs, General Counsel & Corporate Secretary
  • Mr. Doug Randall
    Executive Vice President of Commercial & Business Operations
  • Dr. Douglas Hay
    Senior Vice President of Regulatory Affairs














TENX Stock Analysis - Frequently Asked Questions

Should I buy or sell Tenax Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TENX shares.
View TENX analyst ratings
or view top-rated stocks.

What is Tenax Therapeutics' stock price target for 2024?

2 analysts have issued 12-month price targets for Tenax Therapeutics' shares. Their TENX share price targets range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next year. This suggests a possible upside of 2,085.0% from the stock's current price.
View analysts price targets for TENX
or view top-rated stocks among Wall Street analysts.

How have TENX shares performed in 2023?

Tenax Therapeutics' stock was trading at $2.2280 at the start of the year. Since then, TENX shares have decreased by 87.7% and is now trading at $0.2746.
View the best growth stocks for 2023 here
.

When is Tenax Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our TENX earnings forecast
.

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) released its quarterly earnings data on Monday, November, 13th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01.

When did Tenax Therapeutics' stock split?

Tenax Therapeutics's stock reverse split on the morning of Wednesday, January 3rd 2024. The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO).

How do I buy shares of Tenax Therapeutics?

Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TENX) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -